The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.
 
Yu Fujiwara
No Relationships to Disclose
 
Shumei Kato
Honoraria - Roche
Consulting or Advisory Role - Foundation Medicine; Pfizer/EMD Serono
Speakers' Bureau - Bayer
Research Funding - ACT Genomics; Konica Minolta; OmniSeq; Sysmex
 
Daisuke Nishizaki
No Relationships to Disclose
 
Hirotaka Miyashita
No Relationships to Disclose
 
Suzanna Lee
No Relationships to Disclose
 
Mary K Nesline
Employment - LabCorp; OmniSeq
Stock and Other Ownership Interests - LabCorp; OmniSeq
Patents, Royalties, Other Intellectual Property - Predictive signature assay (Inst)
 
Jeffrey M. Conroy
Employment - Labcorp; OmniSeq
Leadership - OmniSeq
Stock and Other Ownership Interests - LabCorp; OmniSeq
Consulting or Advisory Role - Covaris
Research Funding - OmniSeq
Patents, Royalties, Other Intellectual Property - Oncology based gene expression signatures
Travel, Accommodations, Expenses - Covaris
 
Paul DePietro
Employment - LabCorp
Stock and Other Ownership Interests - LabCorp
Travel, Accommodations, Expenses - LabCorp
 
Sarabjot Pabla
Employment - Omniseq
Patents, Royalties, Other Intellectual Property - Patent pending at Omniseq (Inst)
 
Scott Michael Lippman
Stock and Other Ownership Interests - Biological Dynamics; io9, LLC; Sympto Health
Consulting or Advisory Role - Biological Dynamics; io9, LLC; Sympto Health
Patents, Royalties, Other Intellectual Property - Mission: Co-founder of a company (io9) and co-developer of IP related to genomic predictive biomarkers and novel therapeutics that will power precision immunotherapy, particularly in the clinical use of immune checkpoint inhibitors.
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Caris Life Sciences; Daiichi Sankyo; Datar Genomics; Eisai; EOM Pharmaceuticals; Gaido; Iylon; Loxo; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Prosperdtx; Regeneron; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - NeoGenomics Laboratories; Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - NCI SWOG; TargetCancer Foundation